• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

New hepatitis C virus (HCV) treatment effective

bys25qthea
April 25, 2013
in Chronic Disease, Gastroenterology, Infectious Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. The addition of sofosbuvir to peginterferon-ribavirin was effective at achieving sustained virologic response against HCV genotypes 1, 4, 5 and 6. For HCV genotypes 2 and 3, sofosbuvir and ribavirin was non-inferior to current treatment (peginterferon-ribavirin). 

2. Patients treated with sofosbuvir experienced fewer adverse events overall. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: There are currently six hepatitis C virus (HCV) genotypes. Since the various genotypes respond differently to treatment, the genotype is one factor that influences the therapy chosen for a chronic HCV carrier. Sofosbuvir is a new HCV polymerase inhibitor that demonstrated high sustained virologic response (SVR) during phase 2 trials. In this study, sofosbuvir was successful at achieving SVR against HCV genotypes 1, 4, 5 and 6 when added to current therapies and was also non-inferior to peginterferon-ribavirin against HCV genotypes 2 and 3. Overall, groups treated with sofosbuvir experienced fewer adverse events. Rapid resistance to treatment has been an issue with past HCV treatments, and sofosbuvir continues to show promise since no viral resistance was detected with deep sequencing assays.

The major limitation to this study was the short follow up time of 12 weeks. Although there was early response to the addition of sofosbuvir, HCV is a chronic infection with various factors influencing relapse. Therefore, relapse rates beyond 12 weeks after sofosbuvir and adverse events from long-term treatment with sofosbuvir will need to be included for future studies.

RELATED REPORTS

Machine learning model demonstrates superior screening efficiency for Hepatitis C virus carriers

#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

Click to read the study in NEJM

In-Depth [randomized, open-label, active-control]: This two-part phase 3 trial added sofosbuvir to the current standard of care (peginterferon-ribavirin) for HCV genotypes 1, 4, 5 and 6 (NEUTRINO; n=327) and compared sofosbuvir-ribavirin to peginterferon-ribavirin for HCV genotypes 2 and 3 (FISSION; n=499). The primary endpoint was sustained virologic response at 12 weeks after the end of treatment. This was 90% for patients in the NEUTRINO study and 67% in both groups in FISSION. All common adverse events occurred at a lower rate for the sofosbuvir treated group in FISSION. With the exception of anemia, no hematologic adverse events (such as decreased lymphocyte count, neutrophil count, platelet count) were observed in the sofosbuvir-ribavirin group.

By Jonathan Liu and Mitalee Patil

More from this author: PFO Closure equivalent to medical management in prevention of recurrent stroke, Combo antifungal therapy most effective treatment for cryptococcal meningitis,  Rhinovirus, genes may interact to increase risk of childhood asthma, Functional MRI map for physical pain identified, Glutamine and antioxidant supplementation provide no benefit for critically-ill patients

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: HCVhepatitis CHepCpeginterferonribavirinsofosbuvir
Previous Post

Gut microbes implicated in stroke and heart attacks: new dietary link

Next Post

Health education module reduces parasitic infections

RelatedReports

Study lends support for interferon-free treatment of hepatitis C
2 Minute Medicine

Machine learning model demonstrates superior screening efficiency for Hepatitis C virus carriers

November 29, 2024
#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018
StudyGraphics

#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

September 7, 2023
Screening insufficient for newborns exposed to hepatitis C virus
Gastroenterology

Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

August 31, 2023
Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males
Chronic Disease

Mortality rates among patients successfully treated for hepatitis C still higher than the general population

August 9, 2023
Next Post
Health education module reduces parasitic infections

Health education module reduces parasitic infections

Liver transplant prolongs life in metastatic colorectal cancer

Liver transplant prolongs life in metastatic colorectal cancer

Drainage for hemopericardium is safe and reduces hospital stay

Drainage for hemopericardium is safe and reduces hospital stay

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind July 7, 2025
  • Fecal calprotectin is a useful marker for defining small bowel endoscopic remission in Crohn’s disease
  • Body mass index-specific waist circumference thresholds may improve mortality risk stratification in women
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.